Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03912805 · ClinicalTrials.gov registry record · Phase 2
ET-01 in Subjects With Lateral Canthal Lines, LCL-209
A Phase 2 study, sponsored by Eirion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT03912805 is a Phase 2 study that has completed, run by Eirion Therapeutics. The registered enrollment target is 38 participants.
The verdict
NCT03912805, a Phase 2 study, has completed, sponsored by Eirion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
Interventions
- BIOLOGICAL Vehicle
- BIOLOGICAL botulinum toxin, Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2019-02-27 |
| Est. Completion | 2019-10-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03912805
The ClinicalTrials.gov registry entry for NCT03912805 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eirion Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT03912805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03912805 about?
NCT03912805 is a clinical study titled "ET-01 in Subjects With Lateral Canthal Lines, LCL-209". This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
What is the current status of trial NCT03912805?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2019-02-27. Estimated completion is 2019-10-04.
What interventions are being tested in trial NCT03912805?
The interventions under investigation include: Vehicle (BIOLOGICAL), botulinum toxin, Type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT03912805?
This trial is sponsored by Eirion Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.